Bayer and Kumquat Biosciences have launched a global collaboration worth up to $1.3 billion to develop and commercialize Kumquat’s KRAS G12D inhibitor, a promising treatment targeting a mutation prevalent in pancreatic, colorectal, and lung cancers. The FDA recently cleared Kumquat's investigational new drug application, enabling this collaboration to advance clinical trials rapidly. KRAS mutations are implicated in nearly a quarter of all human cancers, with the G12D variant posing one of the most challenging therapeutic targets. This deal bolsters Bayer’s precision oncology portfolio and reflects ongoing industry efforts to address historically undruggable cancer targets.